TCEANC Inhibitors
Inhibitors of TCEANC function by interfering with multiple cellular processes and pathways that are essential for its role in transcription elongation. For instance, certain inhibitors target key kinases, impeding phosphorylation events that are central to signaling cascades, and directly influencing the regulatory mechanisms in which TCEANC participates. Others act as mTOR inhibitors, disrupting the mTOR signaling that underpins various aspects of transcriptional regulation. By doing so, these inhibitors can substantially diminish the activity of TCEANC, which relies on the proper functioning of these pathways. Similarly, compounds that inhibit cyclin-dependent kinases or heat shock proteins can indirectly impair TCEANC by halting cell cycle progression or destabilizing the protein complex essential for its activity, respectively.
Moreover, specific inhibitors exert their effects by targeting ATP synthesis or DNA replication machinery, thereby indirectly modulating the functional landscape where TCEANC operates. The depletion of ATP disrupts numerous ATP-dependent processes, such as those involving TCEANC, while topoisomerase inhibition can alter transcriptional dynamics critical for TCEANC's activity. Additionally, the inhibition of RNA polymerase II directly affects transcription, thereby reducing the elongation process that TCEANC is known to facilitate. Other compounds can inhibit the nuclear export of proteins or proteasome activity, potentially leading to an accumulation of proteins within the nucleus or an increase in ubiquitinated proteins, respectively. These outcomes can have cascading effects on TCEANC's stability and turnover, further decreasing its activity within its transcriptional context.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
This kinase inhibitor interferes with ATP binding sites of various kinases, disrupting phosphorylation events that are crucial for many signaling pathways. This action can result in reduced activity of TCEANC, which may rely on phosphorylation for its functional interactions. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, it impedes the mTOR pathway which is involved in various cellular processes including transcriptional regulation. The inhibition of this pathway can lead to a decrease in TCEANC activity due to the dependence of transcriptional elongation processes on mTOR signaling. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
A cyclin-dependent kinase inhibitor, it prevents cell cycle progression and transcriptional regulation by inhibiting CDKs. As TCEANC is implicated in transcription elongation, the inhibition of CDKs may hinder TCEANC's role in this process. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
A diterpene triepoxide that inhibits heat shock proteins (HSPs), which are essential for protein folding and stability. By disrupting HSP function, triptolide can indirectly reduce the stability and activity of TCEANC. | ||||||
Oligomycin | 1404-19-9 | sc-203342 sc-203342C | 10 mg 1 g | $149.00 $12495.00 | 18 | |
Targets ATP synthase, thereby depleting cellular ATP levels. Low ATP levels can affect numerous ATP-dependent processes, including those that TCEANC might be involved in, such as transcriptional regulation. | ||||||
Mitoxantrone | 65271-80-9 | sc-207888 | 100 mg | $285.00 | 8 | |
A type II topoisomerase inhibitor that interferes with DNA replication and transcription processes. This can indirectly affect TCEANC activity by altering the transcriptional landscape where TCEANC functions. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An MEK inhibitor that disrupts the MAPK/ERK pathway. As TCEANC is part of the transcription machinery, hindering this pathway may affect transcriptional elongation controlled by TCEANC. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Interacts with DNA and inhibits RNA polymerase, directly affecting transcription. This can lead to a decrease in TCEANC function due to its role in transcription elongation. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
Inhibits transcription elongation by affecting the phosphorylation state of RNA polymerase II, which can reduce the activity of TCEANC involved in this process. | ||||||
Leptomycin B | 87081-35-4 | sc-358688 sc-358688A sc-358688B | 50 µg 500 µg 2.5 mg | $107.00 $416.00 $1248.00 | 35 | |
Inhibits the nuclear export of proteins by binding to exportin 1. Since TCEANC functions within the nucleus, this could result in its functional inhibition due to a failure to interact with necessary nuclear components. | ||||||